Centrexion Therapeutics
Centrexion Therapeutics is a late clinical-stage biopharmaceutical company dedicated to developing and commercializing novel, non-opioid and non-addictive therapies for the treatment of chronic pain. Their mission is to address the large unmet medical need for safe and effective pain relief, leveraging big data analytics, translational science, and innovative clinical trial strategies. They focus on therapies that target the origin of pain signals, aiming to provide durable pain treatment solutions without the risks associated with opioids and other traditional treatments.
Industries
Nr. of Employees
small (1-50)
Centrexion Therapeutics
One Boston Place, Suite 3520, Boston, MA 02108
Patents
Compositions and methods for epidural administration of MCOPPB for pain relief
US-12268679-B1
View Details(4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
US-12076321-B2
View Details
Compositions and methods for epidural administration of MCOPPB for pain relief
US-12268679-B1
View Details(4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
US-12076321-B2
View DetailsProducts
Phase 2 CB2-selective oral small-molecule agonist (CB2-selective oral)
Orally administered small-molecule agonist with reported high selectivity for CB2 over CB1; developed for diabetic peripheral neuropathic pain and shown preclinical receptor selectivity.
Phase 2b SSTR4 agonist (oral)
Orally administered small-molecule somatostatin receptor subtype 4 (SSTR4) agonist in clinical development for chronic neuropathic pain indications.
Phase 2 TrkA inhibitor (intra-articular)
Intra-articular delivery of a TrkA inhibitor being developed for knee osteoarthritis pain (clinical-stage intra-articular therapy).
Phase 2a NOPr agonist (intrathecal)
Spinal/intrathecal delivery of a nociceptin/orphanin FQ peptide receptor (NOPr) agonist in early clinical development for chronic pain.
Phase 2 CB2-selective oral small-molecule agonist (CB2-selective oral)
Orally administered small-molecule agonist with reported high selectivity for CB2 over CB1; developed for diabetic peripheral neuropathic pain and shown preclinical receptor selectivity.
Phase 2b SSTR4 agonist (oral)
Orally administered small-molecule somatostatin receptor subtype 4 (SSTR4) agonist in clinical development for chronic neuropathic pain indications.
Phase 2 TrkA inhibitor (intra-articular)
Intra-articular delivery of a TrkA inhibitor being developed for knee osteoarthritis pain (clinical-stage intra-articular therapy).
Phase 2a NOPr agonist (intrathecal)
Spinal/intrathecal delivery of a nociceptin/orphanin FQ peptide receptor (NOPr) agonist in early clinical development for chronic pain.
Services
Analytical services to identify pain-related biological pathways by applying large-scale data analytics to prioritize targets for therapeutic development.
Evaluation of candidate safety and efficacy in naturally-occurring chronic pain conditions in companion animals to inform human clinical development.
Design and conduct of efficient early-phase clinical trials tailored to pain indications, including program operational management from start-up through execution.
Activities to secure funding, communicate with investors, and establish strategic partnerships to advance clinical-stage programs.
Analytical services to identify pain-related biological pathways by applying large-scale data analytics to prioritize targets for therapeutic development.
Evaluation of candidate safety and efficacy in naturally-occurring chronic pain conditions in companion animals to inform human clinical development.
Design and conduct of efficient early-phase clinical trials tailored to pain indications, including program operational management from start-up through execution.
Activities to secure funding, communicate with investors, and establish strategic partnerships to advance clinical-stage programs.
Expertise Areas
- Clinical trial management
- Translational pain research using companion-animal models
- Non-opioid analgesic drug development
- Mechanism-targeted small-molecule therapeutics
Key Technologies
- Big data analytics for pathway analysis
- Companion-animal translational models
- Adaptive/innovative early-stage clinical trial design
- Oral small-molecule agonists/antagonists